Compare EOG Resources Inc (EOG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs TG Therapeutics Inc — how do they compare? EOG Resources Inc trades at $144 (market cap $75.22B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: EOG Resources Inc is far larger — about 9.8× TG Therapeutics Inc's market cap, and EOG Resources Inc pays a 2.85% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EOG | TGTX | |
|---|---|---|
Market Cap | $75.22B | $7.64B |
Sector | Energy | Health |
52-Week High | $149.89 | $59.06 |
52-Week Low | $101.78 | $26.94 |
Enterprise Value | $78.56B | $7.84B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $142.93, up 0.5% today, with a bullish technical outlook and strong fundamentals. The stock exhibits robust profitability with a 25.81% net income margin and 22.51% ROE, supported by three consecutive quarterly earnings beats. Analysts are overwhelmingly positive with a $157.88 consensus target and no sell ratings. Recent news highlights record Q2 2026 earnings, cost discipline, and promising international exploration.
The outlook for EOG is favorable, driven by strong cash flow generation, shareholder returns, and operational efficiency. Key risks include oil price volatility and capital expenditure intensity. With solid institutional support and a discounted valuation, the stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
